Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | NAAA | Q02083 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.44 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2083526 | 0.85 | CTSK (0.53) | SMN1; SMN2LMNAL3MBTL1MAPTALDH1A1 | |
| SCHEMBL137308 | 0.85 | LMNA (0.65) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL335344 | 0.81 | SMN1; SMN2 (0.52) | SMN1; SMN2LMNAMAPTHTTALDH1A1 | |
| SCHEMBL12439167 | 0.80 | LMNA (0.48) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL3107991 | 0.79 | LMNA (0.58) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL3443629 | 0.79 | NPC1 (0.69) | SMN1; SMN2LMNAMAPTNPC1RAB9A | |
| SCHEMBL22134981 | 0.79 | CHRNB2 (0.58) | SMN1; SMN2LMNAL3MBTL1HTTALDH1A1 | |
| SCHEMBL11191249 | 0.79 | TDP1 (0.53) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL16732162 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2LMNAL3MBTL1MAPTHTT | |
| SCHEMBL21070510 | 0.78 | SMN1; SMN2 (0.64) | SMN1; SMN2LMNAL3MBTL1MAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-8097708-B2 | 10a-Azalide compound | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2012-01-17 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
| US-20090281292-A1 | 10a-Azalide Compound | MEIJI SEIKA PHARMA CO., LTD. (JP) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281292-A1 | 10a-Azalide Compound | IL17A, AZI2, HDAC9 | SMN1; SMN2 3120/4885LMNA 1467/4885L3MBTL1 2853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.